Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s share price shot up 6.5% during mid-day trading on Wednesday . The company traded as high as $10.30 and last traded at $10.78, 5,683 shares traded hands during mid-day trading. A decline of 98% from the average session volume of 307,941 shares. The stock had previously closed at $10.12.
A number of research firms have recently issued reports on SNDX. Morgan Stanley boosted their price target on shares of Syndax Pharmaceuticals from $8.00 to $10.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 11th. Robert W. Baird upped their target price on shares of Syndax Pharmaceuticals from $20.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 4th. Barclays started coverage on shares of Syndax Pharmaceuticals in a research note on Wednesday, March 4th. They set an “overweight” rating and a $15.00 target price on the stock. Citigroup upped their target price on shares of Syndax Pharmaceuticals from to in a research note on Thursday, March 12th. Finally, Nomura reaffirmed a “buy” rating and set a $16.00 target price on shares of Syndax Pharmaceuticals in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Syndax Pharmaceuticals has an average rating of “Buy” and an average price target of $15.94.
The firm’s 50 day moving average is $9.89 and its two-hundred day moving average is $8.34. The stock has a market capitalization of $307.84 million, a PE ratio of -5.39 and a beta of 2.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.39 and a current ratio of 3.39.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.02. Syndax Pharmaceuticals had a negative net margin of 3,694.59% and a negative return on equity of 112.35%. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.38 million. On average, analysts anticipate that Syndax Pharmaceuticals Inc will post -2.11 EPS for the current year.
In other news, CEO Briggs Morrison purchased 12,500 shares of the stock in a transaction on Tuesday, February 4th. The stock was bought at an average price of $10.01 per share, for a total transaction of $125,125.00. Insiders own 8.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in Syndax Pharmaceuticals by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 300,201 shares of the company’s stock worth $2,635,000 after acquiring an additional 13,963 shares in the last quarter. Algert Global LLC grew its holdings in Syndax Pharmaceuticals by 46.4% during the 4th quarter. Algert Global LLC now owns 25,580 shares of the company’s stock worth $225,000 after acquiring an additional 8,110 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in Syndax Pharmaceuticals by 27.8% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 101,952 shares of the company’s stock worth $895,000 after acquiring an additional 22,208 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Syndax Pharmaceuticals by 3.7% during the 4th quarter. Bank of New York Mellon Corp now owns 74,987 shares of the company’s stock worth $658,000 after acquiring an additional 2,642 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in Syndax Pharmaceuticals by 172.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 62,042 shares of the company’s stock worth $545,000 after acquiring an additional 39,305 shares in the last quarter. Institutional investors own 55.16% of the company’s stock.
Syndax Pharmaceuticals Company Profile (NASDAQ:SNDX)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.